Contrasting Chugai Pharmaceutical (OTCMKTS:CHGCY) & Jinhua Marine Biological (OTCMKTS:JNMB)

Jinhua Marine Biological (OTCMKTS:JNMB) and Chugai Pharmaceutical (OTCMKTS:CHGCY) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Valuation & Earnings

This table compares Jinhua Marine Biological and Chugai Pharmaceutical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jinhua Marine Biological	N/A	N/A	N/A	N/A	N/A
Chugai Pharmaceutical	$8.41 billion	8.45	$2.91 billion	$0.92	23.47

Chugai Pharmaceutical has higher revenue and earnings than Jinhua Marine Biological.

Profitability

This table compares Jinhua Marine Biological and Chugai Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jinhua Marine Biological	N/A	N/A	N/A
Chugai Pharmaceutical	35.09%	23.76%	19.92%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Jinhua Marine Biological and Chugai Pharmaceutical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jinhua Marine Biological	0	0	0	0	0.00
Chugai Pharmaceutical	0	3	1	1	2.60

Insider & Institutional Ownership

0.0% of Chugai Pharmaceutical shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Chugai Pharmaceutical beats Jinhua Marine Biological on 8 of the 8 factors compared between the two stocks.

About Jinhua Marine Biological

Jinhua Marine Biological (USA), Inc. develops allopelagic materials, biological medicines, pesticides, environmental protection products, and products for the home. It offers health products, including Xiduoan, which is used for strengthening and adjusting the immune system. The company also introduces advanced wastewater treatment technology, as well as develops environmental protection projects, including industry/urban wastewater treatment. This business was pursued in three areas: the development, manufacture, distribution and sale of ERGOS Systems directly by the Company; consulting services, and the delivery of marketing and other services to ERGOS network providers.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.